NEW YORK, May 10, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that data related to ITI-007, the Company’s lead product candidate, will be featured in several poster presentations at the following meetings:
- The 2016 Society of Biological Psychiatry (SOBP) Annual Meeting to be held from May 12-14, in Atlanta, Georgia.
- The 2016 American Psychiatric Association (APA) Annual Meeting, to be held from May 14-18, also in Atlanta, Georgia.
The poster presentations will feature data from the Company’s two positive ITI-007 schizophrenia clinical studies to date, highlighting this product candidate’s unique pharmacology, mechanism of action, and efficacy in combination with its favorable safety and tolerability in the treatment of schizophrenia.
Poster presentation #1036: “Unique Pharmacology of ITI-007 Confers Efficacy in the Treatment of Schizophrenia at Low Striatal D2 Receptor Occupancy Levels,” will be presented on Saturday, May 14th from 5:00 p.m. to 7:00 p.m. EDT at Grand Hall West - LL2, Atrium Tower, Hyatt Regency Atlanta.
Poster presentation #P6-146: “ITI-007 for the Treatment of Schizophrenia: Primary & Secondary Efficacy Endpoints and Subgroup Analyses from Two Positive Randomized, Double-Blind, Placebo-Controlled Trials,” will be presented on Monday, May 16th from 2:00 p.m. to 4:00 p.m. EDT at Exhibit Hall B3-B4, Georgia World Congress Center.
Poster presentation #P6-147: “ITI-007 for the Treatment of Schizophrenia: Safety & Tolerability Data to Date from Two Double-Blind, Randomized, Placebo-Controlled Clinical Trials,” will be presented on Monday, May 16th from 2:00 p.m. to 4:00 p.m. EDT at Exhibit Hall B3-B4, Georgia World Congress Center.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our clinical and non-clinical development plans; the progress, timing and results of our clinical trials; the safety and efficacy of our product development candidates; our beliefs about the potential uses and benefits of ITI-007; and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to the following: our current and planned clinical trials, other studies for ITI-007, and our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.
Contact: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 646-440-9333 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) email@example.com 212-213-0006
Source:Intra-Cellular Therapies, Inc.